In psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-
and-error approach. The prescribing of these medications is complicated by sub-optimal …

Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, has been
characterized by significant inter-individual variability in drug response and the development …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here,
presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and …

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used
psychopharmaceutical treatment for major depressive disorder (MDD), but individual …

Due to the chronic relapsing nature of mental disorders and increased life expectancy, the
societal burden of these non-communicable diseases will increase even further. Treatments …

Variability in hepatic cytochrome P450 (CYP) enzymes such as 2C19 and 2D6 may
influence side-effect and efficacy outcomes for antipsychotics. Aripiprazole and risperidone …

Pharmacogenetics (PGx) is the study and application of how interindividual differences in
our genomes can influence drug responses. By evaluating individuals' genetic variability in …

(1) Background Pharmacological treatment for psychiatric disorders has shown to only be
effective in about one-third of patients, as it is associated with frequent treatment failure …

Background: Prescribing drugs for psychosis (antipsychotics) is challenging due to high
rates of poor treatment outcomes, which are in part explained by an individual's genetics …

Background: Presently, there is limited guidance on the maximal dosing of psychosis drugs
that is based on effectiveness rather than safety or toxicity. Current maximum dosing …